Business Standard

Aurobindo Pharma posts net profit of Rs 92 cr in Q3

The Hyderabad-based firm had posted a net loss of Rs 28.54 crore for the corresponding period of previous fiscal

Related News

today posted consolidated net profit of Rs 91.81 crore for the third quarter ended December 31, 2012, on the back of robust sales across domestic and international markets.

The Hyderabad-based firm had posted a of Rs 28.54 crore for the corresponding period of previous fiscal.   

Consolidated net sales of the company rose to Rs 1,551.95 crore for the third quarter, as compared to Rs 1,263.73 crore for the same period of 2011-12 fiscal, Aurobindo Pharma Ltd said in a statement.

"We continue to see traction on our performance both in sales and earnings on year on year basis on account of improved business mix in formulations from new product approvals and launches in the US market," Aurobindo Pharma Ltd Managing Director N Govindarajan said.

He added that during the quarter, the US Food and Drug Administration (USFDA) cleared its two units and the health regulator has started approving products from these facilities.

"These will pave the way for consolidating injectable formulations business," Govindarajan added.

The company said its board also approved an of 100%, Re 1 per equity share of Re 1 for the year 2012-13.

Shares of Aurobindo Pharma today ended at Rs 186.55 on the BSE, down 3.07% from their previous close.

Read more on:   
|
|
|
|

Read More

ACC consolidated net profit down 19% at Rs 1,059-cr in 2012

Cement maker ACC today reported a 18.6% dip in consolidated net profit for the year 2012 at Rs 1,059 crore as it changed the method of calculating ...

Quick Links

Results Calendar
Rss icon September 2014 Rss icon
Sun Mon Tue Wed Thu Fri Sat
123456
78910111213
14151617181920
21222324252627
282930
Results Tracker
Available for 3894 companies
Quarter Jun 2014 Jun 2013 % chg
Sales 1,749,372.13 1,585,052.91 10.37
Op. Profit 448,722.78 377,756.43 18.79
Net Profit 113,352.14 81,353.51 39.33
Figures in Rs crore
Advertisement

Back to Top